3/28/2024 | BKCVHY | Fitch raises Jazz
|
1/25/2024 | BKCVHY | Moody’s upgrades Jazz Pharmaceuticals
|
1/8/2024 | BK | Market Commentary: Zelis, Clarios tweak deals; Inspire, Citadel, Caliber, Jane, DirecTV and more set talk
|
10/20/2023 | HY | Market Commentary: Junk: Global Aircraft needs more time; Venture better; cruisers hit headwinds, NCL at new low
|
10/20/2023 | HY | Market Commentary: Morning Commentary: Venture Global notes hover below issue prices; Jazz up on sale news
|
7/5/2023 | BKCVHY | S&P moves Jazz outlook to positive
|
1/20/2023 | BKCVHY | Moody's views Jazz Pharma positively
|
7/8/2022 | CV | Market Commentary: Upstart convertible notes tank on earnings warning; Jazz Pharmaceuticals in focus
|
5/25/2022 | HY | Market Commentary: Buyers return to HY secondary; BB credits lifted post-Fed minutes; Frontier hits new heights
|
5/13/2022 | BKCVHY | Fitch revises Jazz outlook to positive
|
4/11/2022 | BKCVHY | Moody's turns Jazz Pharma view to stable
|
8/4/2021 | CV | Market Commentary: Alphatec on tap; Envestnet in focus; Jazz down outright, expands dollar-neutral
|
5/24/2021 | SP | New Issue: Barclays sells $364,000 trigger autocallable contingent yield notes on Jazz Pharmaceuticals
|
5/5/2021 | BKCVHY | S&P cuts Jazz Pharmaceuticals
|
4/23/2021 | BKCVDDEMIGPV | Market Commentary: Triple-hook deals in Friday junk primary; Jazz, Imperial Dade at a premium; goeasy gains
|
4/23/2021 | HY | Market Commentary: Triple-hook deals in Friday junk primary; Jazz, Imperial Dade at a premium; goeasy gains
|
4/22/2021 | HY | Market Commentary: Four junk issuers sell $3 billion; MidCap breaks 103, Primo Water on a par-handle
|
4/22/2021 | BK | Market Commentary: Jazz, Wells Fargo, Signature, FleetCor, Parts Authority break; Resonetics changes emerge
|
4/22/2021 | CLHY | Market Commentary: Jazz, Wells Fargo, Signature, FleetCor, Parts Authority break; Resonetics changes emerge
|
4/22/2021 | HY | New Issue: Jazz Pharmaceuticals prices downsized $1.5 billion 4 3/8% notes due 2029 at par
|
4/22/2021 | HY | Jazz Pharmaceuticals talks downsized $1.5 billion eight-year secured notes at 4 5/8% area
|
4/22/2021 | BK | Jazz Pharmaceuticals lifts term loan B to $3.85 billion equivalent
|
4/21/2021 | BKCVHY | S&P rates Jazz notes BB-
|
4/20/2021 | BKCVDDEMIGPV | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
4/20/2021 | HY | Market Commentary: High yield: Morgan Automotive prices; Jazz megadeal on tap; Charter flat; Emergent down again
|
4/20/2021 | BKCVHY | Fitch rates Jazz notes BB+
|
4/20/2021 | HY | Jazz Pharmaceuticals starts roadshow for $2.7 billion eight-year notes; initial talk high 4% area
|
4/20/2021 | BKCVHY | Moody's assigns Jazz Pharma notes Ba2
|
4/19/2021 | HY | Jazz Pharmaceuticals expected to bring $2.7 billion notes this week; whisper is high 4% area
|
4/12/2021 | BK | Market Commentary: ArcLight NGPL breaks; Jazz, United Airlines, UPC, GMS, Cision release price guidance
|
4/12/2021 | CLHY | Market Commentary: ArcLight NGPL breaks; Jazz, United Airlines, UPC, GMS, Cision release price guidance
|
4/12/2021 | BK | Jazz Pharmaceuticals reveals talk on $2.65 billion equivalent term B
|
4/9/2021 | BKCVHY | Fitch assigns Jazz Pharmaceuticals BB-
|
4/9/2021 | BK | Market Commentary: Hunter Fan, Aecom, Frontier Communications, TI Group free to trade; Aptean releases talk
|
4/9/2021 | CLHY | Market Commentary: Hunter Fan, Aecom, Frontier Communications, TI Group free to trade; Aptean releases talk
|
4/9/2021 | BKCVHY | Moody's gives Jazz Pharma facilities Ba2
|
4/9/2021 | BK | Jazz Pharmaceuticals to launch $2.65 billion equivalent term B Monday
|
4/9/2021 | BKCVHY | S&P rates Jazz loan BB-
|
2/4/2021 | BKCV | S&P puts Jazz Pharmaceuticals on watch
|
2/4/2021 | BKHY | Jazz Pharmaceuticals gets $5.85 billion debt commitment for GW buy
|
2/4/2021 | BKCV | Moody’s reviews Jazz for downgrade
|
2/3/2021 | CV | Market Commentary: MakeMyTrip, Pebblebrook add-on on tap; Mitek skyrockets on debut; U.S. Steel in focus
|
2/3/2021 | BK | Jazz Pharmaceuticals plans new debt financing for GW purchase
|
11/4/2020 | CV | Market Commentary: Novocure, Lyft, Jazz Pharmaceuticals jump as ballot counts continue past Election Day
|
10/9/2020 | CV | Market Commentary: Fiverr convertibles continue to rise; Sunpower skyrockets; Jazz, ON Semiconductor active
|
10/9/2020 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals, ON Semiconductor convertibles active early
|
6/17/2020 | CV | Market Commentary: Allegheny Technologies, GlaxoSmithKline exchangeables eyed; Jazz, Palo Alto top par
|
6/15/2020 | CV | Market Commentary: Convertibles primary market quiet; Pioneer Natural, Southwest Airlines, Jazz volatile
|
6/15/2020 | CV | Market Commentary: Morning Commentary: Convertibles quiet early; Palo Alto, Jazz Pharmaceuticals down
|
6/12/2020 | CV | Market Commentary: Zendesk, LivaNova convertibles hit aftermarket, trade up on debut; Coupa tops par
|
6/9/2020 | CV | Market Commentary: Coupa, WisdomTree convertibles on deck; Okta, Aptiv eyed; Jazz flat; Glaukos volatile
|
6/9/2020 | CV | Market Commentary: Morning Commentary: Okta convertibles eyed; Aptiv on deck; Jazz flat; Glaukos volatile
|
6/9/2020 | CV | New Issue: Jazz Pharmaceuticals prices $850 million six-year exchangeables to yield 2%, up 40%
|
6/8/2020 | CV | Market Commentary: Jazz to price $850 million exchangeable; Glaukos offers seven-year convertible notes
|
6/8/2020 | CV | Market Commentary: Morning Commentary: Jazz to price $850 million exchangeable; Glaukos offers seven-year paper
|
6/8/2020 | CV | Jazz Pharmaceuticals offers $850 million six-year exchangeable notes
|
6/8/2020 | CV | Jazz Pharmaceuticals offers $850 million six-year exchangeable notes
|
10/8/2019 | CV | Market Commentary: Convertibles market weighed by equities downturn; primary quiet; NXP Semiconductors eyed
|
1/4/2019 | CV | Market Commentary: Ensco convertible notes eyed as crude oil futures bounce; Medicines sees large seller
|
12/21/2018 | CV | Market Commentary: Benefitfocus convertibles hit the market, trade up; Illumina expands; Jazz contracts
|
11/7/2018 | CV | Market Commentary: Zillow, Mindbody, Jazz Pharmaceuticals, Twilio, Etsy active; Infinera ‘disaster du jour’
|
10/29/2018 | CV | Market Commentary: Red Hat convertibles active on buyout, trade at double par; Jazz up; Weatherford tanks
|
10/29/2018 | CV | Market Commentary: Morning Commentary: Red Hat active on buyout, trades at double par; Jazz notes improve
|
6/7/2018 | BK | Jazz Pharmaceuticals expands revolver, adds term loan
|
3/29/2018 | CV | Market Commentary: Chegg upsized, expands on market debut; Tesla rebounds; Jazz Pharmaceuticals active
|
1/9/2018 | CV | Market Commentary: Wheeler to price add on to 8.75% preferreds; Insulet in demand; GoPro holders hold on
|
9/5/2017 | CV | Market Commentary: Convertible debt investors eye recent deals from II-VI, Jazz; hurricanes pressure insurers
|
9/5/2017 | CV | Market Commentary: Morning Commentary: Convertible debt investors eye recent deals from II-VI, Jazz Pharmaceuticals
|
9/1/2017 | CV | Market Commentary: Convertibles quiet ahead of long weekend; Palo Alto Networks up in line; Acorda off lows
|
9/1/2017 | CV | Jazz Pharmaceuticals greenshoe ups 1.5% exchangeables to $575 million
|
8/25/2017 | CV | Market Commentary: II-VI’s new 0.25% five-year notes active, give in a little; Jazz softer; Tesla falters
|
8/24/2017 | CV | Market Commentary: Convertibles move sideways in quiet trade; new II-VI surges in first-day trading
|
8/22/2017 | CV | Market Commentary: II-VI plans new Rule 144A deal; Jazz edges above issue price; Red Hat busy; Teva assets eyed
|
8/22/2017 | CV | Market Commentary: Morning Commentary: Jazz’s recent deal pushes above issue price; Red Hat, Palo Alto active
|
8/21/2017 | CV | Market Commentary: Convertibles activity wanes; Herbalife gains on news; Vipshop dips; Illumina tracks stock
|
8/18/2017 | CV | Market Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady; DyCom sees action
|
8/18/2017 | BKCV | Moody’s upgrades Jazz debt
|
8/18/2017 | CV | Market Commentary: Morning Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady
|
8/18/2017 | CV | New Issue: Jazz sells $500 million 1.5% seven-year exchangeables at 97, up 50%
|
8/17/2017 | CV | Market Commentary: GAIN comes in line; Hannon trades near par post-pricing; Jazz plans deal; Altbaba notes firm
|
8/17/2017 | BK | Jazz Pharmaceuticals to repay revolver borrowings via note offering
|
8/17/2017 | CV | Jazz Pharmaceuticals offers $500 million exchangeables due 2024; price talk 1.5%, up 50%
|
6/14/2017 | SP | New Issue: JPMorgan sells $1 million contingent buffered notes on basket of seven stocks
|
5/30/2017 | SP | JPMorgan plans capped contingent buffered notes linked to seven stocks
|
4/11/2017 | BK | Moody’s revises Jazz Securities to stable
|
3/21/2017 | CV | Market Commentary: Tesla’s convertibles weaken as stock markets broadly sell off; oil-services names lower
|
3/21/2017 | CV | Market Commentary: Morning Commentary: Jazz Pharmaceuticals, Vipshop trading firm to better despite stock markets’ sag
|
6/1/2016 | BKCV | Moody’s lowers Jazz to negative
|
5/31/2016 | PP | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
5/31/2016 | BK | Jazz Pharmaceuticals to tap bank loans for $1.5 billion Celator buyout
|
5/31/2016 | CV | Market Commentary: Morning Commentary: Health care in focus as sector lifts following Celator acquisition news
|
5/12/2016 | PP | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
5/12/2016 | CV | Market Commentary: Qihoo convertibles slip back; YY trades; health care mostly lower; Jazz, Horizon down
|
5/12/2016 | CV | Market Commentary: Morning Commentary: Qihoo 360 convertibles, shares ease; Horizon Pharma, Jazz bonds down
|
4/13/2016 | PP | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/13/2016 | CV | Market Commentary: Health care convertibles mixed; energy ‘trickles back’; China-related names active on data
|
4/7/2016 | PP | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
4/7/2016 | CV | Market Commentary: Healthcare flies higher as out-of-favor sector enjoys resurgence; DepoMed, BioMarin improve
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
7/28/2015 | SP | New Issue: UBS prices $4.55 million trigger phoenix autocallables tied to Jazz Pharmaceuticals
|
7/22/2015 | SP | UBS plans trigger phoenix autocallables linked to Jazz Pharmaceuticals
|
7/8/2015 | BKCV | Jazz Pharmaceuticals eyes growth through acquisitions, says CFO
|
6/23/2015 | SP | New Issue: UBS sells $2.28 million contingent absolute return autocallables on Jazz Pharmaceuticals
|
6/18/2015 | BK | Jazz Pharmaceuticals obtains $1.5 billion five-year credit agreement
|
6/18/2015 | SP | UBS plans contingent absolute return autocallable notes linked to Jazz
|
6/9/2015 | SP | New Issue: RBC prices $1.39 million 7.2% airbag autocallables linked to Jazz
|
6/4/2015 | SP | RBC to price 6%-7.2% airbag autocallables tied to Jazz Pharmaceuticals
|
5/1/2015 | SP | New Issue: HSBC prices $2.68 million 7% airbag autocallables linked to Jazz Pharmaceuticals
|
4/22/2015 | SP | HSBC plans 6%-8% airbag autocallables linked to Jazz Pharmaceuticals
|
4/21/2015 | SP | JPMorgan plans autocallable contingent interest notes linked to Jazz
|
4/21/2015 | SP | New Issue: JPMorgan prices $1.23 million contingent interest autocallables on Jazz Pharmaceuticals
|
4/15/2015 | SP | New Issue: UBS prices $904,000 contingent absolute return autocallables on Jazz Pharmaceuticals
|
4/14/2015 | SP | JPMorgan plans autocallable contingent interest notes linked to Jazz
|
4/8/2015 | SP | UBS to price contingent absolute return autocallable notes linked to Jazz Pharmaceuticals
|
1/30/2015 | SP | New Issue: JPMorgan prices $4.97 million 8.8% airbag autocallables linked to Jazz
|
1/27/2015 | SP | JPMorgan to price 7%-8.8% airbag autocallables on Jazz Pharmaceuticals
|
10/30/2014 | SP | New Issue: Morgan Stanley prices $1.11 million 8.25% airbag autocallables on Jazz
|
10/23/2014 | SP | Morgan Stanley plans airbag autocallable yield notes on Jazz Pharma
|
8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/26/2014 | SP | New Issue: RBC prices $1.75 million trigger phoenix autocallables linked to Jazz
|
8/20/2014 | SP | RBC plans trigger phoenix autocallable notes on Jazz Pharmaceuticals
|
8/20/2014 | PP | Market Commentary: Convertibles see better buyers; Jazz Pharmaceuticals outperforms; Royal Gold holds gains
|
8/20/2014 | CV | Market Commentary: Convertibles see better buyers; Jazz Pharmaceuticals outperforms; Royal Gold holds gains
|
8/20/2014 | SP | New Issue: JPMorgan prices $2.03 million trigger phoenix autocallables on Jazz Pharmaceuticals
|
8/18/2014 | PP | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
8/18/2014 | CV | Market Commentary: Gilead Sciences active, trading below parity; Priceline off a bit; USEC convertibles flat
|
8/13/2014 | CV | Jazz Pharmaceuticals greenshoe lifts exchangeable sale to $575 million
|
8/8/2014 | CV | New Issue: Jazz Pharmaceuticals sells $500 million exchangeables due 2021 at 1.875%, up 47.5%
|
8/7/2014 | BKCV | S&P gives Jazz exchangeables B+
|
7/23/2014 | SP | New Issue: Morgan Stanley prices $2.15 million 9% airbag autocallables linked to Jazz
|
7/15/2014 | SP | Morgan Stanley plans 7.1%-9.1% airbag autocallables on Jazz
|
6/5/2014 | SP | New Issue: Barclays prices $2.35 million callable contingent coupon notes on Jazz
|
5/30/2014 | SP | New Issue: JPMorgan prices $1.72 million 8.65% airbag autocallables tied to Jazz
|
5/21/2014 | SP | JPMorgan to price 7%-9% airbag autocallables linked to Jazz
|
5/15/2014 | SP | New Issue: UBS prices $2 million contingent income autocallables linked to Jazz Pharmaceuticals
|
5/14/2014 | SP | New Issue: Barclays prices $2.35 million contingent coupon notes linked to Jazz
|
1/15/2014 | BK | S&P affirms Jazz on upsizing
|
12/24/2013 | SP | New Issue: JPMorgan prices $1.06 million 7.8% airbag yield notes linked to Jazz
|
12/23/2013 | BK | Jazz Pharmaceuticals $500 million loan expected at Libor plus 275 bps
|
12/19/2013 | BK | Jazz Pharmaceuticals plans $500 million term loans for Gentium buy
|
12/19/2013 | SP | JPMorgan plans 7%-9% airbag yield optimization notes linked to Jazz
|
1/23/2013 | SP | New Issue: JPMorgan prices $2.3 million contingent absolute return autocallables linked to Jazz
|
1/14/2013 | SP | JPMorgan to price contingent absolute return autocallables linked to Jazz Pharmaceuticals
|
6/12/2012 | BK | Market Commentary: Revel term loan falls some more; ResCap better with Berkshire bid; Tank, LHP, WOW set talk
|
6/11/2012 | BK | Jazz Pharmaceuticals reduces term loan B size to $475 million
|
6/11/2012 | BK | Market Commentary: Jazz Pharmaceuticals, Kronos break; EnergySolutions down with revised guidance, Revel dips
|
6/5/2012 | BK | Jazz Pharmaceuticals raises pricing on $600 million credit facility
|
6/5/2012 | BK | Market Commentary: Hearthside breaks; Alaska Communications trades up; Jazz, Wastequip, Elo Touch tweak deals
|
5/21/2012 | BK | S&P assigns Jazz Pharmaceuticals loan BBB-
|
5/16/2012 | BK | Jazz Pharmaceuticals reveals talk on $600 million credit facility
|
5/16/2012 | BK | Market Commentary: NGPL, Grohe, Hub break; Momentive up on paydown; Chesapeake slides; Granite reworks deal
|
5/14/2012 | BK | Jazz Pharmaceuticals sets Wednesday launch for $600 million facility
|
5/14/2012 | BK | Market Commentary: Arch Coal frees up; Bausch & Lomb launches delayed-draw syndication; Jazz reveals timing
|
4/27/2012 | BK | Jazz Pharmaceuticals expects to launch $600 million facility in May
|